| |
Are you enabling your commercial strategy with connected healthcare information? Do you have an optimized infrastructure to manage data consumption, streamline integration, and produce analytics that reflect a complete patient journey? Learn more. 
|
|
|
September 30- October 1, 2024| Boston, MA
The Fierce New Product Planning Summit is the only conference focused on how life science professionals make informed, value-based, data-driven decisions about pipeline products. Experts gather annually to discuss resource utilization and key questions for commercial success. Stay Updated! 
|
|
| By Helen Floersh Women have long shouldered the burden of birth control. Now, men may soon have an option that is not only hormone-free, but also allows space between doses. |
|
|
|
By Fraiser Kansteiner Starting this month, BMS will begin the process of laying off around 863 employees in Lawrenceville, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) alert from the state. The move forms part of BMS’ campaign to shave off $1.5 billion in costs by the end of 2025, a company spokesperson said over email. |
By Gabrielle Masson While 2022 offered quite a few R&D leadership shake-ups, 2023 proved much calmer, with one whopping standout—a $20 million payout for Johnson & Johnson’s new head of pharma R&D. |
By Ben Adams,Andrea Park,Nick Paul Taylor AbbVie has toppled Sanofi and Regeneron as the biggest drug ad spender across the pharmaceutical industry in 2023 with a major victory for its next-gen immunology blockbuster Skyrizi. |
By Angus Liu After Akeso and Summit's ivonescimab beat Keytruda in a head-to-head trial in non-small cell lung cancer, analysts are trying to sort out the financial ramifications while biopharma insiders are eager to see the exact data. But what does Merck think? |
By Annalee Armstrong Pharmas have a record $1 trillion to deploy on new innovative deals. All they need is for the Federal Reserve to lower rates, according to a new report from Ernst & Young. |
By Gabrielle Masson A new trend has emerged at this year’s American Society of Clinical Oncology conference: the possibility of replacing decades-old chemotherapy with novel approaches. AbbVie wants to "be part of that wave." |
By Fraiser Kansteiner A little less than a year after Eli Lilly won the blessing of England's drug value watchdog for tirzepatide in Type 2 diabetes, the National Institute for Health and Care Excellence (NICE) has returned with an endorsement in obesity. However, this time, the organization’s green light has some caveats. |
By Annalee Armstrong A Special Report from the Fierce Biotech team on the state of cell therapy. |
By Conor Hale The company’s board of directors has approved the plan for Grail to join the Nasdaq, under the ticker “GRAL,” before the end of this month. |
By Nick Paul Taylor The multiple myeloma market is booming. Bloomberg Intelligence (BI) forecasts sales will hit $33 billion in 2030, up almost $10 billion on last year, as Johnson & Johnson wrestles control of the blood cancer market from Bristol Myers Squibb. |
By Joseph Keenan Eli Lilly appointed Melissa Seymour as executive vice president of global quality as the pharma giant looks to expand manufacturing capacity to meet booming demand for its diabetes and obesity drugs. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," we explore therapeutic psychedelics. Noah Tong from Fierce Healthcare sat down with Kim Chew, Senior Counsel at Husch Blackwell, to discuss the accessibility challenges in this promising but complex space. |
|
|---|
|
|
|
July 8-9, 2024 | Jersey City, NJ Hear the latest industry trends from leaders in the field, and developed input from our esteemed advisory board, to ensure you have a sound plan for your company, brands, and yourself. Save $200 when you register today! 
|
|
Webinar Watch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
Research Learn how a Top-10 Pharma company automated the extraction of oncology efficacy endpoints from scientific literature with high precision and recall using a combination of AI technologies. Sponsored by: IQVIA |
eBook This eBook offers insights for business leaders looking to do more with reduced budgets by using the power of SmartIQ’s true forms automation to eliminate the need to print, sign, and scan/mail physical documents, increase operational efficiency, and reduce disparate systems. Sponsored by: SmartComms LLC |
Research Download this research report to discover how a new predictive model built on consumer attitudinal data can generate improved results for health marketers. Sponsored by: Quad Media |
Whitepaper Virtual care programs represent a compelling opportunity for decision makers in life sciences companies to drive growth, innovation, and value creation. Download now to learn more. Sponsored by: Wheel |
Whitepaper How one top pharma increased literature reviews efficiency by 3x powered by AI -- download today Sponsored by: IQVIA |
Whitepaper Small molecule active pharmaceutical ingredients (APIs) continue to grow more complex. Download the white paper to learn more about using synthesis and route design technology to approach API complexity. Sponsored by: Lonza |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper This paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
